Sakin, A. Et Al. 2019. The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the secand-line setting for metastatic pancreatic cancer patients with poor performance status. TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY , 85-89.

Sakin, A., Şahin, S., Atci, M. M., Demir, C., Yasar, N., Geredeli, C., ... Cihan, S.(2019). The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the secand-line setting for metastatic pancreatic cancer patients with poor performance status. TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY , 85-89.

Sakin, Abdullah Et Al. "The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the secand-line setting for metastatic pancreatic cancer patients with poor performance status," TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY , 85-89, 2019

Sakin, Abdullah Et Al. "The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the secand-line setting for metastatic pancreatic cancer patients with poor performance status." TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY , pp.85-89, 2019

Sakin, A. Et Al. (2019) . "The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the secand-line setting for metastatic pancreatic cancer patients with poor performance status." TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY , pp.85-89.

@article{article, author={Abdullah Sakin Et Al. }, title={The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the secand-line setting for metastatic pancreatic cancer patients with poor performance status}, journal={TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY}, year=2019, pages={85-89} }